Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  05/26 11:35:23 am EDT
103.60 EUR   -0.12%
05:48aSanofi - European Week Against Cancer 2022 - Interview with Santiago Aguirre, Market Lead Europe Oncology, Sanofi
AQ
05/25SANOFI : FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis - Form 6-K
PU
05/25French health body backs new COVID vaccine booster campaign for this autumn
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
05/20/2022 05/23/2022 05/24/2022 05/25/2022 05/26/2022 Date
102.3(c) 103.7(c) 103.62(c) 103.72(c) 103.6(c) Last
2 409 766 1 670 660 1 851 699 1 667 343 1 361 866 Volume
+2.24% +1.37% -0.08% +0.10% -0.12% Change
More quotes
Estimated financial data (e)
Sales 2022 41 710 M 44 744 M 44 744 M
Net income 2022 7 983 M 8 564 M 8 564 M
Net Debt 2022 6 544 M 7 020 M 7 020 M
P/E ratio 2022 16,2x
Yield 2022 3,41%
Sales 2023 43 238 M 46 383 M 46 383 M
Net income 2023 8 166 M 8 760 M 8 760 M
Net Debt 2023 984 M 1 056 M 1 056 M
P/E ratio 2023 15,8x
Yield 2023 3,52%
Capitalization 129 B 139 B 139 B
EV / Sales 2022 3,26x
EV / Sales 2023 3,01x
Nbr of Employees 95 442
Free-Float 88,3%
More Financials
Company
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (71.5%): prescription drugs in the areas of general medicine (52.7% of net sales; mainly for the treatment of diabetes and cardiovascular diseases) and specialty medicine (47.3%; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune... 
Read more
Sector
Pharmaceuticals
Calendar
06/03Presentation
More about the company
Ratings of Sanofi
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about SANOFI
05:48aSanofi - European Week Against Cancer 2022 - Interview with Santiago Aguirre, Market Le..
AQ
05/25SANOFI : FDA approves Dupixent® (dupilumab) as first treatment for adults and children age..
PU
05/25French health body backs new COVID vaccine booster campaign for this autumn
RE
05/23Fitch Raises Sanofi's Outlook To Positive From Stable on Transition Plan, Profitability
MT
05/22France's Sanofi Wins US FDA Nod for Eosinophilic Esophagitis Drug
MT
05/20Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis
MT
05/20PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first treatment for adults and child..
GL
05/20PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first treatment for adults and child..
AQ
05/20Sanofi's Dupixent wins U.S. approval for bigger use
RE
05/20FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment
DJ
05/20SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/20Sanofi's Xenpozyme Secures Positive Opinion From the European Medicines Agency's CHMP
MT
05/18TRANSCRIPT : Sanofi - Special Call
CI
05/17Sanofi Announces New Nirsevimab Data Analyses Reinforce Efficacy Against RSV
CI
05/17ASCO - New data from fast-growing innovative Oncology pipeline and portfolio to be pres..
AQ
More news
News in other languages on SANOFI
05/24Les valeurs à suivre aujourd'hui à la Bourse de Paris - Mardi 24 mai 2022
05/24GENOWAY : A suivre aujourd'hui
05/23Les valeurs à suivre demain à la Bourse de Paris - Mardi 24 mai 2022
05/23GENOWAY : propose la nomination d'Olivier Charmeil (Sanofi) au poste d'administrateur
05/23CAC40 : entame de semaine hésitante, les taux remontent
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 05/02
The underlying trend is to the upside
BUY
More Stock Trading Analysis
Analysis
EuroAPI gains on market debut after spin-off from Sanofi
Stock Pick
 SANOFI
The road to reinvention
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 103,60 €
Average target price 115,21 €
Spread / Average Target 11,2%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI17.09%138 292
JOHNSON & JOHNSON5.00%472 652
PFIZER, INC.-9.04%301 361
ROCHE HOLDING AG-12.16%281 908
ELI LILLY AND COMPANY11.15%276 358
ABBVIE INC.12.23%268 530